PECAM-1 (CD 31) mediates transendothelial leukocyte migration in experimental colitis
Authors:
- Emile RijckenEREmile Rijcken
- Rudolf B. MennigenRMRudolf B. Mennigen
- Sebastian D. SchaeferSSSebastian D. Schaefer
- Mike G. LaukoetterMLMike G. Laukoetter
- Christoph AnthoniCAChristoph Anthoni
- Hans-Ullrich SpiegelHSHans-Ullrich Spiegel
- Matthias BruewerMBMatthias Bruewer
- Norbert SenningerNSNorbert Senninger
- Christian F. KrieglsteinCKChristian F. Krieglstein
- 1 August 2007
- journal article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 293 (2) , G446-G452
Abstract
Transendothelial migration of circulating leukocytes into the colonic wall is a key step in the development of the inflammatory infiltrate in inflammatory bowel disease (IBD). The platelet-endothelial cell adhesion molecule-1 PECAM-1 (CD31) is expressed in the tight junction area of endothelial cells, where it is supposed to support the transmigration process. The aim of this study was to determine the role of PECAM-1 in experimental IBD and to show whether blockade of PECAM-1 has therapeutic effects. Chronic colitis was induced in female BALB/c mice by cyclic oral administration of dextran sodium sulfate (DSS) 3% (wt/vol). Expression of PECAM-1 was visualized by immunohistochemistry. In the treatment group animals received 1 mg/kg anti-PECAM-1 (2H8) ip daily starting on day 26. On day 30 leukocyte adhesion and migration was measured during N2O-isoflurane anesthesia in the distal colon by intravital microscopy. Disease activity index (DAI), histology, and MPO levels were compared with healthy and diseased controls. PECAM-1 was expressed in colitic mice. Chronic DSS colitis was characterized by a marked increase in rolling, adherent, and transmigrated leukocytes compared with healthy controls. Immunoblockade of PECAM-1 reduced leukocyte transmigration significantly and also diminished leukocyte rolling and sticking in an indirect manner. It also resulted in a significantly diminished DAI and MPO levels, as well as an amelioration of the histological inflammation score. PECAM-1 plays an important role in transendothelial leukocyte migration in DSS colitis. PECAM-1 could be a novel target for antibody-based treatment in IBD.Keywords
This publication has 35 references indexed in Scilit:
- CD40–CD40 Ligand Mediates the Recruitment of Leukocytes and Platelets in the Inflamed Murine ColonGastroenterology, 2007
- The role of JAM-A and PECAM-1 in modulating leukocyte infiltration in inflamed and ischemic tissuesJournal of Leukocyte Biology, 2006
- Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitisAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2006
- Differential expression and regulation of murine CD40 in regional vascular bedsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Attenuation of Leukocyte Sequestration by Selective Blockade of PECAM-1 or VCAM-1 in Murine EndotoxemiaEuropean Surgical Research, 2004
- Immunoblockade of PSGL-1 attenuates established experimental murine colitis by reduction of leukocyte rollingAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- Blockade of Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) Protects against Ischemia-Reperfusion Injury in Muscle Flaps at Microcirculatory LevelPlastic and Reconstructive Surgery, 1999
- Molecular and functional aspects of PECAM-1/CD31Immunology Today, 1994
- Altered expression of cell adhesion molecules in uninvolved gut in inflammatory bowel diseaseClinical and Experimental Immunology, 1993
- Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporinDigestive Diseases and Sciences, 1993